C4 Therapeutics to Participate in Upcoming March Conferences

About this update from C4 Therapeutics, Inc.

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science, today announced that C4T management will participate in two upcoming March conferences. The live webcasts will be available on the Investors section of the company’s website at www.c4therapeutics.com . The archived replays of the webcasts will be available for approximately 90 days following the events. About C4 Therapeutics C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ®  platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit  www.c4therapeutics.com . Contacts: Investors: Courtney Solberg Associate Director, Investor Relations [email protected] Media: Loraine Spreen Senior Director, Corporate Communications & Patient Advocacy [email protected]

View stock analysis, news, and events for C4 Therapeutics, Inc.